Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis.
Ataş Ü, Salim O, Iltar U, Yücel OK, Küçükdiler Eroğlu AH, Aslan V, Yıldırım M, Dedeoğlu Ö, Seçilmiş S, Ulaş T, Deveci B, Karaman Gulsaran S, Gedük A, Yaman F, Pınar İE, Maral S, Sarıcı A, Çelik S, Oğul H, Gülkan Özkan S, Gemici A, Güneş AK, Tombak A, Yavaşoğlu İ, Karakuş V, Cömert M, Toptaş T, Dal MS, Saba R, Kırkızlar HO, Mehtap Ö, Gündüz E, Özkalemkaş F, Albayrak M, Berber İ, Keklik M, Güler N, Özkan HA, Sevindik ÖG, Bolaman Z, Kurtoğlu E, Aylı M, Fıratlı Tuğlular T, Altuntaş F, Ündar L. Ataş Ü, et al. Among authors: maral s. Turk J Haematol. 2024 Dec 2;41(4):225-235. doi: 10.4274/tjh.galenos.2024.2023.0450. Epub 2024 Nov 6. Turk J Haematol. 2024. PMID: 39501735 Free PMC article.
Azacitidine-related pyoderma gangrenosum.
Maral S, Uzunabdullah E, Zilan Yamis N, Kuzucular E, Surul B, Gokmen Sevindik O. Maral S, et al. Ann Dermatol Venereol. 2024 Nov 1;152(1):103323. doi: 10.1016/j.annder.2024.103323. Online ahead of print. Ann Dermatol Venereol. 2024. PMID: 39488194 No abstract available.
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
Yiğit Kaya S, Mutlu YG, Malkan ÜY, Mehtap Ö, Keklik Karadağ F, Korkmaz G, Elverdi T, Saydam G, Özet G, Ar MC, Melek E, Maral S, Kaynar L, Sevindik ÖG. Yiğit Kaya S, et al. Among authors: maral s. Leuk Res. 2024 May;140:107495. doi: 10.1016/j.leukres.2024.107495. Epub 2024 Mar 29. Leuk Res. 2024. PMID: 38599153
37 results